Swiss - Delayed Quote CHF

Novartis AG (NOVNEE.SW)

91.14

-1.42

(-1.53%)

As of 9:41:28 AM GMT+2. Market Open.

Novartis (NVS) is a Great Momentum Stock: Should You Buy?

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks yesterday

NVS
Why Novartis (NVS) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Zacks yesterday

NVS
Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

LA Times 4 days ago

NVS

RGLS
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr

TipRanks 5 days ago

NVS

NVSEF

RGLS
Novartis to strengthen renal disease portfolio with Regulus

Total consideration for the acquisition, including the CVR, could reach $1.7bn.

Pharmaceutical Technology 5 days ago

NVS

RGLS
Why Novartis (NVS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 6 days ago

NVS
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks 6 days ago

EXAS

NVS
Novartis to acquire Regulus in deal for kidney disease drug

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.

BioPharma Dive 6 days ago

NVS

RGLS
Novartis to Acquire Regulus in $1.7 Billion Deal

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

The Wall Street Journal 6 days ago

NVS

NVSEF

RGLS
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million, and another $7 per share to Regulus shareholders if the lead drug candidate, farabursen, gets regulatory approval, the California-based biotech said on Wednesday. The deal, expected to bolster Novartis' lineup of kidney disease drugs in development, will also give the company access to Regulus' proprietary platform to develop treatments targeting a type of genetic material called microRNAs.

Reuters 6 days ago

NVS

RGLS
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory milestone;

GlobeNewswire 6 days ago

NVS

NVSEF
Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements

Novartis AG (NVS) reports robust sales and income growth, while navigating challenges and enhancing its product pipeline.

GuruFocus.com 7 days ago

NVS
Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point

Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.

Investor's Business Daily 7 days ago

NVS

NVSEF
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 7 days ago

NVS
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up

NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.

Zacks 7 days ago

NVS
Novartis: Q1 Earnings Snapshot

BASEL, Switzerland (AP) — Novartis AG (NVS) on Tuesday reported first-quarter net income of $3.61 billion. On a per-share basis, the Basel, Switzerland-based company said it had net income of $1.83. Earnings, adjusted for non-recurring costs, were $2.28 per share.

Associated Press Finance 7 days ago

NVS
Novartis Lifts Guidance After Profit, Sales Top Views

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.

The Wall Street Journal 8 days ago

NVS

NVSEF
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali (+56% cc), Kesimpta (+43% cc), Cosentyx (+18% cc), Leqvio (+72% cc) and Scemblix (+76% cc) Core operating income margin1 reached 42.1%, +400 basis points (cc), mainly driven by higher net sales Operating income grew +44% (cc, +38% USD); net income up +37% (cc, +34% USD)Core EPS1 grew +

GlobeNewswire 8 days ago

NVS

NVSEF
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global pricing inequities. Richard Saynor told Reuters that the proposal - outlined in a letter to the Financial Times last week - ignores structural drivers of high drug prices in the United States. "It made me smile, made me laugh," Saynor said of the proposal, adding that he thinks the Trump administration will succeed in driving down prices for brand-name medicines.

Reuters 8 days ago

NVS
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?

President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days. Regardless, corporations are looking for ways to avoid paying these tariffs.

Motley Fool 10 days ago

JNJ

NVS

Performance Overview

Return	NOVNEE.SW	MSCI WORLD (^990100-USD-STRD)
YTD	+3.02%	-0.86%
1-Year	+3.19%	+8.73%
3-Year	+7.29%	+33.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NOVNEE.SW)

Novartis (NVS) is a Great Momentum Stock: Should You Buy?

Why Novartis (NVS) is a Great Dividend Stock Right Now

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Biotech Alert: Searches spiking for these stocks today

Novartis to strengthen renal disease portfolio with Regulus

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Novartis to acquire Regulus in deal for kidney disease drug

Novartis to Acquire Regulus in $1.7 Billion Deal

Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements

Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point

Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics

Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up

Novartis: Q1 Earnings Snapshot

Novartis Lifts Guidance After Profit, Sales Top Views

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access

These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?

Performance Overview